摘要
粘多糖贮积症II型或Hunter综合征是由溶酶体酶IururnAT-2-硫酸酯酶基因突变引起的X连锁溶酶体贮积病。随之产生的酶恶性导致糖胺聚糖进行性多系统积聚,这也是重症患者中枢神经系统临床表现的原因。疾病。目前对亨特综合征、造血干细胞移植和重组酶替代疗法的限制,主要是在脑成就方面。鼓励了一些研究认为基因治疗是一种潜在的治疗选择。体外研究首次以病毒载体介导的Id为例S基因的表达可导致转导细胞的酶活性升高。所取得的令人鼓舞的成果,使许多临床前研究得以实现。F基因治疗载体在动物模型的粘多糖病II,连同一期临床试验批准亨特患者受轻度形式的疾病。到体内重组载体直接、系统地或直接注射到中枢神经系统的微管,以及体内外基因治疗,包括自体移植。造血干细胞,在体外改造,进入动物或病人,已经过测试。目前所取得的结果在临床上得到了更广泛的应用,这对于确保基因治疗是必要的。这一罕见但危及生命的疾病,已被证实为一种有效的治疗方案。
关键词: 载体,逆转录病毒,腺病毒,基因,酶,中枢神经系统。
Current Gene Therapy
Title:Genetics and Gene Therapy in Hunter Disease
Volume: 18 Issue: 2
关键词: 载体,逆转录病毒,腺病毒,基因,酶,中枢神经系统。
摘要: Mucopolysaccharidosis type II or Hunter syndrome is an X-linked lysosomal storage disease caused by a mutation in the gene encoding the lysosomal enzyme iduronate-2-sulfatase. The consequent enzyme deficiency causes a progressive, multisystem accumulation of glycosaminoglycans, which is the cause of the clinical manifestations involving also Central Nervous System for patients with the severe form of disease. The limits of the currently available therapies for Hunter syndrome, hematopoietic stem cell transplantation and recombinant enzyme replacement therapy, mainly regarding brain achievement, have encouraged several studies which recognized gene therapy as a potential therapeutic option for this condition. In vitro studies firstly aimed at the demonstration that viral vector- mediated IDS gene expression could lead to high levels of enzyme activity in transduced cells. The encouraging results obtained allowed the realization of many preclinical studies investigating the utilization of gene therapy vectors in animal models of Mucopolysaccharidosis II, together with a phase I clinical trial approved for Hunter patients affected by the mild form of the disease. Together to in vivo studies in which recombinant vectors are directly administered, systematically or by direct injection into Central Nervous System, also ex vivo gene therapy, consisting in transplantation of autologous hematopoietic stem cells, modified in vitro, into the animal or patient, has been tested. A wider clinical application of the results obtained so far is essential to ensure that gene therapy can be definitively validated as a therapeutic option available and usable for this rare but life-threatening disorder.
Export Options
About this article
Cite this article as:
Genetics and Gene Therapy in Hunter Disease, Current Gene Therapy 2018; 18 (2) . https://dx.doi.org/10.2174/1566523218666180404155759
DOI https://dx.doi.org/10.2174/1566523218666180404155759 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting the Eph System with Peptides and Peptide Conjugates
Current Drug Targets Peripheral Immune Signatures in Alzheimer Disease
Current Alzheimer Research Prostaglandin E Synthase: A Novel Drug Target for Inflammation and Cancer
Current Pharmaceutical Design The Host Complement System and Arbovirus Pathogenesis
Current Drug Targets Tropism-Modified Adenoviral and Adeno-Associated Viral Vectors for Gene Therapy
Current Gene Therapy Disorders of Respiration and Sleep-Disordered Breathing in Patients with Chronic Renal Failure
Current Respiratory Medicine Reviews Immune Restoration Disease: A Consequence of Dysregulated Immune Responses After HAART
Current HIV Research Macrocyclic Lactone Anthelmintics: Spectrum of Activity and Mechanism of Action
Current Pharmaceutical Biotechnology Intracellular Bioinorganic Chemistry and Cross Talk Among Different -Omics
Current Topics in Medicinal Chemistry Structural and Functional Relationships Between GSK3α and GSK3β Proteins
Current Biotechnology Lipid Nanoparticles for the Delivery of Biopharmaceuticals
Current Pharmaceutical Biotechnology Current Pharmacologic Management of Pediatric Heart Failure in Congenital Heart Disease
Current Vascular Pharmacology A Review of PCSK9 Inhibitors and their Effects on Cardiovascular Diseases
Current Topics in Medicinal Chemistry Flavonoids and Related Compounds in Parasitic Disease Control
Mini-Reviews in Medicinal Chemistry Mouse Models of Autoimmune Diseases
Current Drug Discovery Technologies Macrophage Heterogeneity: Relevance and Functional Implications in Atherosclerosis
Current Vascular Pharmacology Neuroinflammation, Oxidative Stress and the Pathogenesis of Alzheimers Disease
Current Pharmaceutical Design Current Options and Perspectives in the Treatment of Diabetic Neuropathy
Current Pharmaceutical Design Applications of Aptamers in Targeted Imaging: State of the Art
Current Topics in Medicinal Chemistry Neurosteroids and Hepatic Encephalopathy: An Update on Possible Pathophysiologic Mechanisms
Current Molecular Pharmacology